Because molecular targeted therapy provides a better overall survival or progression‐free survival to patients with specific gene alterations, such as EGFR, anaplastic lymphoma kinase (ALK), c‐ros oncogene 1 (ROS1), B‐Raf proto‐oncogene (BRAF), etc., the clinical treatment guidelines recommend the assessment of genetic alterations to stratify patients with advanced NSCLC.4 This evidence concerns the gene BRAF and non-small cell lung carcinoma.